Waylis Therap Drug Patent Portfolio

Waylis Therap owns 6 orange book drugs protected by 19 US patents with Aciphex having the least patent protection, holding only 2 patents. And Coreg Cr with maximum patent protection, holding 8 patents. Given below is the list of Waylis Therap's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8101209 Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles 11 Mar, 2026
Active
US8101209 Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles 11 Sep, 2025
Active
US7268156 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment 27 Dec, 2023 Expired
US7268156 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment 27 Jun, 2023 Expired
US6022562 Medicinal and/or nutritional microcapsules for oral administration 17 Apr, 2016 Expired
USRE40000 Method of treatment for decreasing mortality resulting from congestive heart failure 07 Dec, 2015 Expired
US5565467 Androstenone derivative 20 Nov, 2015 Expired
US6022562 Medicinal and/or nutritional microcapsules for oral administration 17 Oct, 2015 Expired
USRE40000 Method of treatment for decreasing mortality resulting from congestive heart failure 07 Jun, 2015 Expired
US6444673 Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it 14 Aug, 2014 Expired
US6444673 Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it 14 Feb, 2014 Expired
US5045552 Pyridine derivatives having anti-ulcerative activity 08 Nov, 2013 Expired
US5846976 Androstenone derivative 17 Sep, 2013 Expired
US5998427 Androstenones 17 Sep, 2013 Expired
US5045552 Pyridine derivatives having anti-ulcerative activity 08 May, 2013 Expired
US6864257 Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it 02 Mar, 2013 Expired
US6864257 Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it 30 Aug, 2012 Expired
US6319926 Optically active 5H-pyrrolo[3, 4-B]pyrazine derivative, its preparation and pharmaceutical compositions containing it 16 Jul, 2012 Expired
US7381724 Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing same 16 Jul, 2012 Expired


Given below is the list of recent legal activities going on the following drug patents of Waylis Therap.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 21 Jun, 2023 US8101209 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 14 Feb, 2019 US7268156
Payment of Maintenance Fee, 8th Year, Large Entity 29 Jan, 2019 US8101209 (Litigated)
Post Issue Communication - Certificate of Correction 10 Apr, 2018 US8101209 (Litigated)
Change in Power of Attorney (May Include Associate POA) 27 Mar, 2018 US8101209 (Litigated)
Email Notification 27 Mar, 2018 US8101209 (Litigated)
Correspondence Address Change 26 Mar, 2018 US8101209 (Litigated)
Expire Patent 01 Jul, 2016 US7381724
Expire Patent 08 Apr, 2013 US6864257
Recordation of Patent Grant Mailed 24 Jan, 2012 US8101209 (Litigated)
Patent Issue Date Used in PTA Calculation 24 Jan, 2012 US8101209 (Litigated)
Issue Notification Mailed 04 Jan, 2012 US8101209 (Litigated)
Dispatch to FDC 29 Dec, 2011 US8101209 (Litigated)
Application Is Considered Ready for Issue 20 Dec, 2011 US8101209 (Litigated)
Issue Fee Payment Verified 12 Dec, 2011 US8101209 (Litigated)


Waylis Therap's Family Patents

Waylis Therap drugs have patent protection in a total of 17 countries. It's US patent count contributes only to 19.2% of its total global patent coverage. 6 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Waylis Therap Drug List

Given below is the complete list of Waylis Therap's drugs and the patents protecting them.


1. Aciphex

Aciphex is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5045552
(Pediatric)
Pyridine derivatives having anti-ulcerative activity 08 Nov, 2013
(11 years ago)
Expired
US5045552 Pyridine derivatives having anti-ulcerative activity 08 May, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aciphex's drug page


2. Avodart

Avodart is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5565467 Androstenone derivative 20 Nov, 2015
(9 years ago)
Expired
US5846976 Androstenone derivative 17 Sep, 2013
(11 years ago)
Expired
US5998427 Androstenones 17 Sep, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Avodart's drug page


3. Coreg

Coreg is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
USRE40000
(Pediatric)
Method of treatment for decreasing mortality resulting from congestive heart failure 07 Dec, 2015
(8 years ago)
Expired
USRE40000 Method of treatment for decreasing mortality resulting from congestive heart failure 07 Jun, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Coreg's drug page


4. Coreg Cr

Coreg Cr is protected by 8 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8101209
(Pediatric)
Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles 11 Mar, 2026
(1 year, 3 months from now)
Active
US8101209 Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles 11 Sep, 2025
(9 months from now)
Active
US7268156
(Pediatric)
Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment 27 Dec, 2023
(11 months ago)
Expired
US7268156 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment 27 Jun, 2023
(1 year, 5 months ago)
Expired
US6022562
(Pediatric)
Medicinal and/or nutritional microcapsules for oral administration 17 Apr, 2016
(8 years ago)
Expired
USRE40000
(Pediatric)
Method of treatment for decreasing mortality resulting from congestive heart failure 07 Dec, 2015
(8 years ago)
Expired
US6022562 Medicinal and/or nutritional microcapsules for oral administration 17 Oct, 2015
(9 years ago)
Expired
USRE40000 Method of treatment for decreasing mortality resulting from congestive heart failure 07 Jun, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Coreg Cr's drug page


5. Jalyn

Jalyn is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5565467 Androstenone derivative 20 Nov, 2015
(9 years ago)
Expired
US5846976 Androstenone derivative 17 Sep, 2013
(11 years ago)
Expired
US5998427 Androstenones 17 Sep, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jalyn's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Lunesta

Lunesta is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6444673
(Pediatric)
Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it 14 Aug, 2014
(10 years ago)
Expired
US6444673 Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it 14 Feb, 2014
(10 years ago)
Expired
US6864257
(Pediatric)
Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it 02 Mar, 2013
(11 years ago)
Expired
US6864257 Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it 30 Aug, 2012
(12 years ago)
Expired
US6319926
(Pediatric)
Optically active 5H-pyrrolo[3, 4-B]pyrazine derivative, its preparation and pharmaceutical compositions containing it 16 Jul, 2012
(12 years ago)
Expired
US7381724
(Pediatric)
Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing same 16 Jul, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lunesta's drug page